The company received a major regulatory win with the European Commission approving its drug, brensocatib, as the first and only approved therapy for non-cystic fibrosis bronchiectasis in the EU. This approval was based on robust Phase 2 and 3 data and followed an accelerated review. Following this news and other strong clinical updates, the consensus analyst price target for the company's stock has increased significantly, reflecting renewed optimism about its future revenue growth and overall outlook.